Development of antiviral agents toward enterovirus 71 infection  by Pourianfar, Hamid Reza & Grollo, Lara
Journal of Microbiology, Immunology and Infection (2015) 48, 1e8Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comREVIEW ARTICLEDevelopment of antiviral agents toward
enterovirus 71 infectionHamid Reza Pourianfar a,b,*, Lara Grollo ba Iranian Academic Centre for Education, Culture and Research (ACECR)dMashhad Branch,
Mashhad, Iran
b Environment and Biotechnology Centre, Swinburne University of Technology, Melbourne, AustraliaReceived 31 October 2013; accepted 16 November 2013
Available online 21 February 2014KEYWORDS
Antiviral agents;
EV71 infection;
EV71 receptors;
Phytochemicals* Corresponding author. Iranian Aca
Culture and Research (ACECR)dMash
1163, Mashhad, Iran.
E-mail address: pourianfar@acecr.
1684-1182/$36 Copyright ª 2013, Taiw
http://dx.doi.org/10.1016/j.jmii.2013Enterovirus 71 (EV71) infection remains a public health problem at a global level, particularly
in the Asia-Pacific region. The infection normally manifests as handefootemouth disease;
however, it is capable of developing into potentially fatal neurological complications. There
is currently no approved vaccine or antiviral substance available for the prevention or treat-
ment of EV71 infection. This paper, thus, reviews efforts to develop or discover synthetic as
well as naturally occurring compounds directed against EV71 infection. The recent achieve-
ments in cellular receptors of EV71 are also highlighted, and their contribution to the devel-
opment of antiviral drugs against EV71 is discussed in this article.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Enterovirus 71 (EV71) is a pathogenic serotype of the
Picornaviridae family, containing a single positive sense
RNA genome with a length of approximately 7.5 kb.
Detected during a small outbreak in California between
1969 and 1972,1 EV71 has now been turned into one of thedemic Centre for Education,
had Branch, P.O. Box 91775-
ac.ir (H.R. Pourianfar).
an Society of Microbiology. Publ
.11.011most pathogenic Enterovirus serotypes with many out-
breaks occurring around the world, particularly in the Asia-
Pacific region. Although EV71 infection usually manifests
with rashes and vesicular lesions on the hands, feet, and
oral mucosa,2 it sometimes leads to fatal neurological
complications such as aseptic meningitis, encephalitis,
acute respiratory disease, and pulmonary edema.3
Following the large outbreaks in both Malaysia and Taiwan
in the late 1990s,4 new life-threatening outbreaks of EV71
reoccurred in Taiwan in 2001e20025 and in China in 2010.6
There is no approved vaccine or antiviral drug available
for prophylaxis or treatment of EV71 infection to date.7
Therefore, research studies should continue to developished by Elsevier Taiwan LLC. All rights reserved.
2 H.R. Pourianfar, L. Grollonovel EV71 inhibitors and as such, latest achievements in
this field always have to be updated. At least three recent
reviews have detailed a range of studies undertaken in both
fields of EV71: antivirals and vaccines.7e9 However,
compared to EV71 vaccine development, a large number of
research ventures conducted into EV71 antiviral develop-
ment has generated vast information on novel compounds
with anti-EV71 capacity and even improved the under-
standing of EV71ehost interactions. Hence, this review
attempts to provide a focused body of information
regarding the status and challenges of antiviral therapy for
EV71, covering both options: synthetic and natural bioac-
tive compounds. In addition, we discuss how newly
discovered EV71 cellular receptors might lead to new ave-
nues for anti-EV71 drug design.
EV71 structural protein inhibitors
It is well known that variations within capsid proteins
VP1eVP3 of EV71 are responsible for the antigenic diversity
of the virus, whereas neutralization sites are most densely
clustered on VP1.10 Thus, EV71 VP1 inhibitors have been
suggested as one of the first candidates for developing anti-
virals against the viral infection. Thus far, pleconaril has been
known as a viral capsid binder that has exhibited inhibitory
effects against a number of Enteroviruses11,12 except EV71.10
However, a recent study interestingly showed that pleconaril
could significantly increase the viability of EV71-infected
cells and reduce the mortality of EV71-infected mice.13
Therefore, it remains to be investigated whether pleconaril
should be considered a potent EV71 inhibitor.
Among other capsid binders, pyridyl imidazolidinone was
the first to demonstrate notable potencies against EV71
infection in a number of consecutive studies.10,14e17 Pyridyl
imidazolidinone is a new category of capsid binders, gener-
ated by a computer-assisted drug design.10 It is believed that
pyridyl imidazolidinone exerts its antiviral action by fitting
into the viral hydrophobic pocket of VP1.17 In the pyridyl
imidazolidinone family, BPROZ-101 with a half-maximal
inhibitory concentration (IC50) of 0.0012 0.0005 (mM) and
BPROZ-074with an IC50 of 0.0008 0.0001 (mM) exhibited the
most considerable antiviral activities against EV71.17 In
addition to pyridyl imidazolidinone, an EV71 VP1-derived
peptide was also demonstrated to reduce the cytopathic
effects of all EV71 strains from genotypes A, B, and C, with
IC50 values ranging from 6 mM to 9.3 mM in RD cells.
18
EV71 nonstructural protein inhibitors
The seven nonstructural proteins of EV71 are the essential
elements involved in various viral functions including pro-
teases, RNA replication, ATPase activity, RNA helicase ac-
tivity, and RNA replication. Hence, these peptides have
been studied as potential targets for designing antiviral
agents toward EV71.19
2Apro
Recently, it was shown that a six-amino-acid peptide,
LVLQTM, exhibited antiviral potencies against EV71 in HeLacells. This peptide was shown to serve as a substrate
mimetic of the EV71 2Apro that is known to be responsible
for the viral protease activity.20
2B
Little information is available for the function of the 2B
peptide of EV71, but it is thought to be important for EV71
RNA replication.21 In this regard, 4,40-diisothiocyano-2,20-
stilbenedisulfonic acid was shown to prevent EV71 2B ac-
tivity, leading to the inhibition of virus production in RD
cells.22
2C
As a multifunctional protein, EV71 2C has been suggested to
be involved in processing nucleoside triphosphatase activ-
ity23 and synthesis of RNA negative strands.24 Two adeno-
sine analoguesdMetrifudil and N6-benzyladenosinedhave
been demonstrated to interact with the EV71 2C peptide
and inhibit viral infection.25
3A
EV71 3A is highly conserved and serves as a scaffold of the
viral RNA replication complex.19 In this respect, an envir-
oxime mimetic compound, AN-12-H5, was reported to
target the 3A region of EV71 and significantly inhibit an
early stage of EV71 infection after virus binding.26
3Cpro
The EV71 3C peptide acts as a viral protease during the viral
infection of host cells, playing a vital role in the maturation
of virion particles. A study showed that rupintrivir promis-
ingly inhibited EV71 3C by mimicking the substrate of the 3C
protease.27 The anti-EV71 activity of rupintrivir was also
evaluated in vivo,28 where the rupintrivir-treated suckling
mice were largely protected from EV71-caused limb
paralysis. Because of its safety, it has been concluded that
rupintrivir can be suitable for immediate evaluation as a
therapy in EV71-infected individuals with fatal neurological
complications.28
3Dpol
EV71 3Dpol is an RNA-dependent RNA polymerase that serves
as a key element for the viral RNA replication process.
DTriP-22 as a nonnucleoside analogue was shown to inhibit
EV71 infection by reducing the viral RNA accumulation after
virus absorption.29 In addition to DTrip-22, aurintricarbox-
ylic acid (a polyanionic compound) could prevent EV71
infection through interference with 3Dpol in Vero cells.30
Nucleotide analogues
Ribavirin (RBV) in the form of ribavirin triphosphate can
serve as a base analogue of either ATP or GTP. The antiviral
potency of RBV has been presented for a wide range of RNA
viruses in vitro and/or in vivo,31e39 including EV7140 where
Antivirals against EV71 3it reduced the EV71 titer in human and mouse cell lines. It
also decreased the rate of death, morbidity, and succeed-
ing paralysis sequelae in EV71-infected mice.40
In contrast with the afore-mentioned findings, a recent
study showed that RBV failed to protect 1-day-old mice
infected with EV71.13 Additionally, some EV71 strains were
even resistant to RBV at concentrations much higher than
those reported previously.18 In our studies, RBV (applied as
a positive control) could not significantly prevent the EV71
infection in Vero cells and even showed a high degree of
cytotoxicity.41 Thus, further studies are warranted to test
the usefulness of RBV as a positive control in different cell
types and for different EV71 strains.
RNA interference
RNA interference has effectively been exploited as an
antiviral tool against EV71 infection in vitro.42e45 In addi-
tion to in vitro studies, promising results have been
attained through an in vivo study.46 The findings revealed
that the mice treated with 10 nM of 19-mer short inter-
fering RNAs or 50 mg of the plasmid-derived 19-mer small
hair pin RNAs did not develop signs of weight loss or hind
limb paralysis up to 14 days post infection.46
Heparan sulfate mimetics
Heparan sulfate (HS) is present in extracellular matrix, cell
surfaces, and intracellular granule secretions of all types of
animal tissues.47 HS is composed of a basic structure of
sulfated polymers of alternating uronic acid-(1/4)-D-
glucosamine.48 HS mimetics are a group of soluble synthetic
or semisynthetic compounds, structurally related to
cellular HS, which are able to simulate the functions of cell
surface HS.49 Because cellular HS serves as a carbohydrate
receptor for the human viruses of various families,50 HS
mimetics are thus assumed to simulate the function of a
cellular receptor for many of viruses.51 Therefore, HS mi-
metics have significant applications in virology, particularly
for development of antivirals and determination of viral
receptors.52
The antiviral potencies of HS mimetics against EV71
were recently demonstrated by our group.41 Several soluble
HS mimetic compounds, including heparin, pentosan poly-
sulfate, and HS, were shown to exhibit potent antiviral
activities against a cloned strain of EV71 in Vero cells at
noncytotoxic concentrations less than 250 mg/mL, as
opposed to RBV as the positive control. The mode of action
assays revealed that all the compounds were capable of
exerting antiviral activities by hindering viral attachment to
the cells.41
In order to gain insight into the mechanism(s) of action
of heparin against EV71 infection, we followed our studies
with a genome-wide microarray analysis of an EV71-
infected human neural cell line, SK-N-SH. To make the re-
sults more relevant and applicable, microarray analysis was
carried out concurrently with antiviral activity and cyto-
toxicity tests of heparin, analyzed through a multilevel
comparison. Of the more than 30,000 genes studied, 14
well-known annotated genes were selected for which
heparin significantly modified the intensities of genes thathave already been upregulated or downregulated by
EV71.53Type I interferon subtypes
Following the demonstration of a protective effect for type
I interferons (IFNs) toward EV71 infection,54 anti-EV71 po-
tencies of 17 type I IFNs were assayed in Vero cells, where
IFNs a4, a6, a14, and a16 exhibited more antiviral activities
compared with the rest.55 However, further investigations
by the same research group revealed that EV71 was able to
suppress the cellular type I IFN response by reducing IFN
receptor 1 level. Moreover, EV71 2Apro was shown to play a
crucial role in antagonizing the type I IFN response. These
new findings shed light on how EV71 might suppress the host
innate immune response, and thus may assist the devel-
opment of new therapy options for EV71 infection.56Antiviral peptides
Thus far, at least one natural cationic peptided
lactoferrindhas been reported to exert antiviral activities
toward EV71 infection.57 Lactoferrin is an iron-binding
glycoprotein present in milk, saliva, mucous secretions,
and other biological fluids of mammals. Both bovine and
human lactoferrins significantly prevented infection of
isolates of EV71 in RD cells with an IC50 of 10.5e24.5 mg/mL
and 103.3e185.0 mg/mL, respectively. Further in vivo ex-
periments demonstrated that lactoferrin saved 17-day-old
ICR mice from fatal EV71 challenge.58 It was proposed that
lactoferrin exerts its antiviral action through the preven-
tion of viral entry by blocking cellular receptors and/or by
direct binding to the virus.58Other synthetic EV71 inhibitors
N-phenylbenzamide
A series ofN-phenylbenzamidederivativeswere synthesized,
and their antiviral potencies were evaluated against four
strains of EV71dSZ-98, JS-52-3, H, and BrCrdin Vero cells,
where 3-amino-N-(4-bromophenyl)-4-methoxybenzamide
effectively showed an IC50 value ranging from 5.7 0.8 mM
to 12 1.2 mM.597-Hydroxyisoflavone
It was shown that 7-hydroxyisoflavone dose-dependently
exhibited a potent antiviral activity against three different
EV71 strains at an early step of EV71 replication.60Methyl 3,4-dihydroxyphenylacetate
EV71 replication in RD cells was shown to be prevented by
methyl 3,4-dihydroxyphenylacetate. The compound, at a
concentration of 0.01 mg/mL, reduced EV71 VP1 mRNA
48 hours post infection, with a low toxicity on RD cells.61
4 H.R. Pourianfar, L. GrolloBPR3P0128
BPR3P0128, a novel compound with potent inhibitory ef-
fects against influenza, was also shown to significantly
inhibit infection of some RNA viruses, including EV71.62
FLICE-like inhibitory protein
FLICE-like inhibitory protein (FLIP) has been known as a
negative regulator of death ligand-directed apoptosis,
which modulates virus pathogenesis. It was reported that
EV71 replication was noticeably reduced in MRC5 cells
preincubated with anti-FLIP peptides.63
Benzimidazole derivatives
A study showed that one of the screened benzimidazole
derivatives inhibited EV71 infection in Vero cells, with a low
cytotoxicity and an IC50 of 1.76 mg/mL.
64
N-arylethyl isoquinoline derivatives
The antienteroviral activities of a series of synthesized
N-arylethyl isoquinoline derivatives were tested in vitro.
Among these agents, the compound 7f exerted a significant
antiviral activity against Coxsackievirus B3, whereas it
exhibited a moderate activity toward EV71.65
Chloroquine, guanidine hydrochloride, and
cycloheximide
Three compoundsdchloroquine, guanidine hydrochloride,
and cycloheximidedwere shown to prevent EV71-mediated
apoptosis in human glioblastoma cells. Interestingly,
1.2 l mM of chloroquine could reduce EV71 RNA synthesis
more than 90 times.66
Anti-EV71 capacity of phytochemicals
Medicinal plants are considered rich and as yet fully unex-
ploited sources of novel phytochemicals, which are worth
being considered as potential antiviral drugs. Thus far, a
number of naturally occurring compounds have been re-
ported to have antiviral activities toward EV71 infection.
Table 1 lists a number of studies undertaken to examine the
antiviral capacities of several plant- or algae-derived
compounds against EV71 infection.67e84 Many of these
reputable medicinal herbs have a long history of use in
traditional Chinese medicine, which makes them more
applicable for further investigations and less problematic
for humans. Thus, it is not surprising that such research
studies have mostly been undertaken by scientists from the
Asia-Pacific region, where several fatal outbreaks of EV71
have occurred.
Apart from the differences in their antiviral potencies,
phytochemicals tested for EV71 antiviral activity featured
several common characteristics; for example, almost all of
them were shown to exert low cytotoxicity in their antiviral
doses. Whereas the stage in which EV71 is inhibited has
been determined for all compounds, an exact molecularmechanism(s) of action has been drawn for only some of
them, including aloe-emodin,71 the extract of Houttuynia
cordata,72 kappa carrageenan,75 the leaf extract of Kalan-
choe gracilis, and the extract of Paris polyphylla Smith.79
Another aspect is that recent studies on anti-EV71’s influ-
ence of plant-derived compounds have also been per-
formed in an animal model77,80e84 (Table 1).
Screening among local medicinal plants could also be
considered an effective and fast option for the discovery of
anti-EV71 bioactive compounds. In this respect, a study
reported screening 22 Chinese herbs for their anti-EV71
potentialities, leading to selection of the plant, H. cor-
data.72 Consistent with these findings, another study
attempted to screen among 12 commonly used antiviral
herbs that were recommended by Chinese government
agencies for the handefootemouth disease. The results
interestingly revealed that H. cordata was the only remedy
with a potent antiviral activity against both EV71 and
Coxsackievirus A16.73 These findings might warrant follow-
up studies to investigate the exact molecular mechanisms
of action and evaluate the anti-EV71 capacity of this plant
in an animal model.EV71 receptors and their contribution to
antiviral development
To date, several molecules have been identified and char-
acterized to serve as cellular receptors for human entero-
viruses. The most common enteroviral receptors include
glycoproteins such as decay-accelerating factor and the
Coxsackievirus and adenovirus receptor, which mediate
infection for many enteroviral serotypes particularly
echoviruses85 and group B Coxsackieviruses.86 Whereas
there is concrete evidence of viral receptors of human
enteroviruses, the discovery of the possible cell receptors
of EV71 does not have a long history. In fact, the cellular
receptors of EV71 were not clearly elucidated until 2009,
when two research groups independently reported the
discovery of two different receptors for the virus: the
human scavenger receptor class B, member 2 (SCARB2)87
and the human P-selectin glycoprotein ligand-1 (PSGL).88
Since the outstanding discoveries of EV71 receptors,87,88
other molecules have also been suggested as candidate
cellular receptors for EV71, including sialic acid89,90 and
DC-SIGN.91 Furthermore, it was also proven that EV71 uti-
lizes cell surface HS as an attachment receptor in RD
cells.18 Compliant with this finding, our research studies
showed that the highly sulfated domains of cellular HS may
serve as an essential attachment coreceptor for a clinical
isolate of EV71 in Vero cells.92 Later, our DNA microarray
analysis proved that the heparan sulfate 2-O-sulfo-
transferase 1 (HS2ST1) gene was significantly upregulated
by the EV71 infection of neural cells.53 This gene has a role
in the biosynthesis of cell surface HS. These findings sup-
ported the speculation that clinical EV71 required cell
surface HS to infect or bind neural cells, in agreement with
the recent discoveries of the role of HS in mediating EV71
infection.18,92
Although it remains to be investigated how the discov-
ered receptors might contribute to the neurotropism of
EV71, these findings could have implications for the design
Table 1 Anti-EV71 capability of several bioactive compounds from plants and algae
Source/reference Active component Use in folk
medicine
In vitro mechanisms
of action
In vivo assays
Salvia miltiorrhiza
(Danshen)67
Crude extracts of
dried roots
TCM Interference with
viral entry
d
Ocimum basilicum
(sweet basil)68
Ursolic acid TCM Inhibition of viral
replication after infection
d
Five medicinal plants69 Named Sheng-Ma-
Ge-Gen-Tanga
TCM Inhibition of viral
attachment and
penetration
d
Pueraria lobata Ohwi70 Named Ge-Gen-Tang TCM Inhibition of EV71 before
and after infection
d
Rheum palmatum71 Aloe-emodin TCM A potent interferon-
inducer
d
Houttuynia cordata72,73 Water extracts TCM Suppressing EV71-induced
caspase 3 activation
d
Spirulina platensis
(a blue-green alga)74
Allophycocyanin d More effective prior
to viral infection
d
seaweeds75 Kappa carrageenan d Forming virus-
polysaccharide complexes
to prevent viral entry
d
Glycyrrhiza uralensis
Fisch76
Glycyrrhizic acid TCM suppressing EV71
replication after
virus entry
d
Kalanchoe gracilis77 Leaf extractsb TCM Inhibiting EV71 2A
proteases, reducing
EV71-activated caspase 9,
decreasing EV71-induced
up-regulation of IL-6 and
RANTES genes
Inhibiting EV71
replication
in the intestine of
suckling mice
Daphne genkwa78 Extracts of dry
flower buds
TCM Targeting EV71 entry d
Paris polyphylla Smith79 Ethanol extracts TCM Increasing amounts of
IL-6 production
d
Several medicinal
plants80
Punicalaginc TCM Reducing EV71-caused
viral CPE
Reducing mortality of
EV71-challenged mice
Several medicinal
plants81
Matrinec TCM Suppressing EV71 RNA
copy number
Reducing mortality of
EV71-challenged mice
Several medicinal
plants82
Geraniinc TCM Reducing EV71-caused
viral CPE
Reducing mortality of
EV71-challenged mice
Laggera pterodonta83 Chrysosplenetin and
penduletin
TCM Inhibition of EV71 after
infection
d
Terminalia chebula84 Chebulagic acid TCM Reducing EV71-caused
viral CPE
Reducing mortality of
EV71-challenged mice
a Sheng-Ma-Ge-Gen-Tang is a mixture of crude extracts of five medicinal plants: including Pueraria lobata Ohwi, Paeonia lactiflora
Pallas, Cimicifuga foetida L., Glycyrrhiza uralenis Fisch, and Zingiber officinale Roscoe.
b Some of the active components were determined to be ferulic acid, quercetin, and kaempferol.
c The pure compoundsdpunicalagin, matrine, and geraniindcan be found in medicinal plants such as Punica granatum, Sophora
genus, and geraniums, respectively.
CPE Z cytopathic effect; EV71 Z enterovirus 71; TCM Z traditional Chinese medicine.
Antivirals against EV71 5or development of anti-EV71 agents. In this respect, one
straightforward approach would be designing a monoclonal
antibody or a soluble form of a receptor in order to
recognize, mimic, and/or block the receptor. The examples
include the monoclonal antibody and/or soluble forms of
SCARB2,87 PSGL-1,88 and DC-SIGN antibody,91 all of which
have shown potent abilities to block EV71.
Sialic acid-mediated EV71 attachment might suggest
that natural sialic acids in human milk could have a role inpreventing EV71 infection in infants, in addition to other
antibodies present in human milk.89 Likewise, the essential
role of cellular HS in EV71 binding would draw attention to
HS mimetic compounds as candidate anti-EV71 agents.41 In
this respect, a variety of synthetic HS derivatives could be
designed in order to evaluate or improve their anti-EV71
capabilities.
Review of the literature illustrates that none of the re-
ported anti-EV71 compounds has been subjected to human
6 H.R. Pourianfar, L. Grolloclinical trials. However, some synthetic compounds have
promisingly been suggested as potential start points, such
as the 3Cpro inhibitor, rupintrivir.9 This compound has
extensively been characterized in various stages of clinical
trials for other viruses, and may thus be suitable for further
evaluation of its potential benefits in EV71-infected
patients.9
Nowadays, drug discovery from natural products may no
longer be very attractive for global pharmaceutical com-
panies because of business considerations and the percep-
tion that it is not cutting-edge research.93 This issue might
be also the case for plant-derived anti-EV71 compounds.
However, in countries with rich sources of ethno-
pharmaceuticals, it is still reasonable to evaluate natural
products as a complementary approach with promising
perspectives. Such studies would be better directed toward
phytochemicals with a convincing record of use in folk
medicine. Moreover, drawbacks such as complexity of
active components, the lack of information on mechanisms
of action, and the lack of an in vivo assay should be over-
come. Among the anti-EV71 natural compounds studied in
an animal model, one promising candidate would be the
active components of K. gracilis,77 for which an inhibitory
effect on EV71 2A proteases was determined.
Genome-wide analyses such as DNA microarrays could
assist scientists to determine targets and pathways for a
purported antiviral compound. However, such studies have
apparently been limited with EV71; these research efforts
include a study of the expression patterns of EV71 infec-
tion94 and our recent microarray study in which the effect
of heparin on the expression profiles of EV71-infected cells
was analyzed.53
The recent discoveries of cell receptors of EV71 have
shed light into the pathogenesis of the virus. Use of re-
ceptor antagonists is a well-known approach for designing
drugs against a variety of disorders, including infectious
viruses. Hence, newly discovered EV71 receptors could be
considered promising, putative drug targets against viral
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